Recruiting
Primary biliary cholangitis: WCS-PBC-1140
A Phase 3 study in participants with an inadequate response to, or intolerance of, ursodeoxycholic acid.
Home/Areas of Study/Primary Biliary Cholangitis
Our commitment to clinical research for PBC
Primary biliary cholangitis is a rare autoimmune liver disease that damages the bile ducts slowly, over years. Our studies are for people whose response to first-line therapy has been inadequate.
~9 in 10
people diagnosed with PBC are women, most between 40 and 60
3 studies in this area
Featured trials
A selection of what is open right now. Eligibility is decided by the investigator at a study site, never by this page.
Recruiting
PBC with pruritus: WCS-PBC-1162
A Phase 2 study evaluating an agent for the persistent itch associated with PBC.
Studies open and close continually. We can text you when a new one opens near you.
Get study alertsOur research
What are we studying?
Learn more about our areas of research and see whether one of our clinical trials might be right for you.
Inadequate response to first-line therapy
- Ursodeoxycholic acid is the standard first treatment, and it works well for many people — but roughly 40% do not respond adequately.
- Inadequate response is the single strongest predictor of progression to cirrhosis, so it is where a second-line option matters most.
- Eligibility is based on liver blood tests, chiefly alkaline phosphatase.
Living with the symptoms
- Fatigue and itch are the symptoms people report as most disruptive, and neither tracks neatly with how advanced the disease is on paper.
- Itch in particular is undertreated, partly because it is hard to measure.
- One of our studies addresses it directly rather than as a secondary endpoint.
Want to understand what taking part actually involves before you go further?
Read the guide